Kenvue (NYSE:KVUE) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Kenvue (NYSE:KVUE) in a report released on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $27.00 target price on the stock.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of Kenvue from $22.00 to $24.00 and gave the stock an overweight rating in a report on Wednesday, August 7th. Piper Sandler lifted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a neutral rating in a research report on Monday. UBS Group lifted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a neutral rating in a research report on Wednesday, August 7th. Citigroup lowered their price objective on shares of Kenvue from $21.00 to $20.00 and set a neutral rating on the stock in a research report on Wednesday, July 10th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a buy rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $22.10.

Kenvue Stock Up 0.5 %

Shares of NYSE KVUE opened at $23.12 on Tuesday. Kenvue has a 1 year low of $17.67 and a 1 year high of $23.55. The stock has a market capitalization of $44.27 billion, a P/E ratio of 29.64, a P/E/G ratio of 2.92 and a beta of 1.40. The company has a 50-day moving average price of $21.21 and a 200-day moving average price of $20.03. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. On average, equities research analysts forecast that Kenvue will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.55%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is 105.13%.

Institutional Trading of Kenvue

Hedge funds and other institutional investors have recently modified their holdings of the business. Manchester Capital Management LLC raised its position in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the period. Mather Group LLC. bought a new stake in Kenvue during the 1st quarter worth approximately $28,000. Riverview Trust Co bought a new stake in Kenvue during the 1st quarter worth approximately $33,000. MV Capital Management Inc. increased its holdings in Kenvue by 71.2% during the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after acquiring an additional 642 shares during the period. Finally, Salomon & Ludwin LLC bought a new stake in Kenvue during the 1st quarter worth approximately $33,000. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.